Volume 1.19 | May 25

Hematopoiesis News 1.19, May 25, 2010.  
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe

TOP STORY

Systems Biology Helps to Understand Hematopoiesis
Researchers combined experimental data with mathematical models in a systems biology approach to study the effect of erythropoietin level on hematopoietic cells. [Press release from EurekAlert! discussing online prepublication in Science]

MethoCult®  
MethoCult®
The most published medium for hematopoietic CFC assays

by STEMCELL Technologies
 
 
TEST YOUR COLONY IDENTIFICATION SKILLS STEMCELL Technologies Inc
 


SCIENCE NEWS

Early Clamping May Interrupt Humankind’s First “Natural Stem Cell Transplant,” the Researchers Report
Delaying clamping the umbilical cord for a slightly longer period of time allows more umbilical cord blood to transfer from mother to infant and, with that critical period extended, many good physiological “gifts” are transferred through ‘nature’s first stem cell transplant’ occurring at birth. [Press release from the University of South Florida discussing online prepublication in the Journal of Cellular and Molecular Medicine]

Drug in New Class of Targeted Therapies Shows Early Promise Against Blood-Related Cancers
A Phase I clinical trial of SNS-032, one of the first in a new class of drugs that inhibit cyclin-dependent kinases, demonstrated the drug’s safety and potential clinical action against advanced chronic lymphocytic leukemia. [Press release from Hackensack University Medical Center discussing online prepublication in the Journal of Clinical Oncology]

Celgene’s Revlimid Positive in Maintenance Trials
Two major studies of Celgene Corp’s multiple myeloma drug Revlimid showed that when taken as maintenance therapy following stem cell transplantation it reduced the risk of disease progression by more than 50 percent. [Reuters Press Release]

Need to expand CD34+ cells?
StemSpan® serum-free expansion media are optimized for expanding hematopoietic stem and progenitor cells
DOWNLOAD THE TECHNICAL BULLETIN STEMCELL Technologies Inc


CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

LABORATORY RESEARCH

Covering a Broad Dynamic Range: Information Processing at the Erythropoietin Receptor
Researchers show by mathematical modeling of quantitative data and experimental validation that rapid ligand depletion and replenishment of cell surface receptor are characteristic features of the erythropoietin receptor. [Science]

Glutaredoxin 5 Deficiency Causes Sideroblastic Anemia by Specifically Impairing Heme Biosynthesis and Depleting Cytosolic Iron in Human Erythroblasts
Researchers report that GLRX5 is essential for iron-sulfur cluster biosynthesis and the maintenance of normal mitochondrial and cytosolic iron homeostasis in human cells. [J Clin Invest]

SENP1-Mediated GATA1 DeSUMOylation is Critical for Definitive Erythropoiesis
Collectively, researchers conclude that SENP1 promotes GATA1 activation and subsequent erythropoiesis by deSUMOylating GATA1. [J Exp Med]

Regulatory Functions of TRAIL in Hematopoietic Progenitors: Human Umbilical Cord Blood and Murine Bone Marrow Transplantation
It is concluded that TRAIL does not trigger apoptosis in hematopoietic progenitors, and upregulation of its cognate receptors under stress conditions mediates tropic signaling that supports recovery from hypoplasia. [Leukemia]

IL-34 and M-CSF Share the Receptor Fms But Are Not Identical in Biological Activity and Signal Activation
The findings indicate that macrophage phenotype and function are differentially regulated even at the level of the single receptor, Fms. [Cell Death Differ]

CXCR4-Independent Rescue of the Myeloproliferative Defect of the Gata1(Low) Myelofibrosis Mouse Model by Aplidin®
In this paper, researchers used the hypomorphic Gata1(low) mouse model of primary myelofibrosis, the most severe of these neoplasms, to test the hypothesis that defective marrow hemopoiesis and development of extramedullary hematopoiesis in myelofibrosis is due to insufficient p27(Kip1) activity and is treatable by Aplidin®, a cyclic depsipeptide that activates p27(Kip1) in several cancer cells. [J Cell Physiol]

Expression of microRNA-451 in Normal and Thalassemic Erythropoiesis
The results suggest that early erythroid progenitors in beta-thalassemia have a dysregulated miRNA-451 expression program, and analysis of microRNA is a relevant approach to determine abnormalities of erythropoiesis. [Ann Hematol]

CLINICAL RESEARCH

Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Hematologic Malignancies After Dose-Escalated Treosulfan/Fludarabine Conditioning
Treosulfan was introduced recently as a conditioning agent for allogeneic blood stem-cell transplantation. The favorable nonhematologic toxicity profile at 3 x 10 g/m(2) was the basis for dose escalation in this prospective, multicenter trial. [J Clin Oncol]

A Molecular Classifier for Predicting Future Graft Loss in Late Kidney Transplant Biopsies
In an attempt to identify molecules that could provide this information, researchers used micorarrays to analyze gene expression in 105 for-cause biopsies taken between 1 and 31 years after transplantation. [J Clin Invest]


INDUSTRY NEWS

Maryland Stem Cell Research Commission Announces 42 Projects for Funding
The Maryland Stem Cell Research Commission has completed its evaluation of the 141 applications in response to its three official Requests for Applications during the FY 2010 funding cycle. [Maryland Stem Cell Research Commission Press Release]

HHMI Awards $79 Million for Science Education to Research Universities, Top Scientists
Howard Hughes Medical Institute announced new grants totaling $79 million that will help universities strengthen undergraduate and precollege science education nationwide. [Howard Hughes Medical Institute Press Release]

AstraZeneca Reaches U.S. Agreement with Teva Pharmaceuticals Regarding Entocort EC Capsules
AstraZeneca announced that it has entered into an agreement with Teva Pharmaceuticals USA, Inc. to settle patent litigation regarding Teva’s proposed generic version of AstraZeneca’s Entocort EC (budesonide) capsules. [AstraZeneca Press Release]

Pfizer to Cut 6,000 Jobs, Close Eight Plants
Pfizer Inc. plans to eliminate 6,000 manufacturing jobs over the next 18 months to five years as it closes eight plants and reduces operations at six others. [St. Louis Business Journal]

Rensselaer Polytechnic Institute Wins $2.45 Million Grant To Support Stem Cell Research
Rensselaer Polytechnic Institute and principal investigator Glenn Monastersky have been awarded a four-year $2.45 million grant from the New York Stem Cell Science Program of the Empire State Stem Cell Board. [Rensselaer Polytechnic Institute Press Release]


POLICY NEWS

House Nixes More Research Spending in COMPETES Bill
Catching the Democratic leadership by surprise, members voted 292 to 126 to block passage of a 5-year authorization bill that would have provided healthy increases in the research and education budgets of the National Science Foundation and research programs at the Department of Energy and the Department of Commerce. [House of Representatives, United States]

NIH Wants More (Not Total) Disclosure of Financial Conflicts
The federal government proposed an overhaul of regulations covering financial conflicts of interest in biomedical research. The rules would expand the amount of information that researchers must report to their institutions, make some of it public, and require that more details than in the past be submitted privately to the National Institutes of Health. [National Institutes of Health, United States]

NIH Requests Comments on the Proposed Rule Applicable to Regulations on the Responsibility of Applicants for Promoting Objectivity in Research for which Public Health Service Funding is Sought and Responsible Prospective Contractors (NOT-OD-10-099) [National Institutes of Health, United States]

Notice of Format Clarification and Frequently Asked Questions (FAQs) for Funding Opportunity Announcement (FOA): RFA-HL-11-006, Next Generation Genetic Association Studies (U01) (NOT-HL-10-110) [National Institutes of Health, United States]

Responsibility of Applicants for Promoting Objectivity in Research for Which Public Health Service Funding Is Sought and Responsible Prospective Contractors; Proposed Rule (Docket Number: NIH-2010-0001) [National Institutes of Health, United States]

Charter of the Blood Products Advisory Committee (Update) [Food and Drug Administration, United States]

FDA Transparency Initiative: Draft Proposals for Public Comment Regarding Disclosure Policies of the U.S. Food and Drug Administration; Availability [Docket No. FDA-2009-N-0247] [Food and Drug Administration, United States]


EVENTS

International Scientific Symposium; Stem Cells in Biology and Disease
May 26-28, 2010
Lisbon, Portugal

International Society for Stem Cell Research (ISSCR) 8th Annual Meeting
June 16-19, 2010
San Francisco, United States

XXXIst International Congress of the International Society of Blood Transfusion (ISBT) in joint cooperation with the 43rd Congress of the German Society for Transfusion Medicine and Immunohematology (DGTI)
June 26-July 1, 2010
Berlin, Germany

The European Molecular Biology Organization (EMBO) Meeting 2010
September 4-7, 2010
Barcelona, Spain

Stem Cells USA & Regenerative Medicine Congress 2010
September 13-15, 2010
Philadelphia, United States

Society for Hematology and Stem Cells (ISEH) 2010 Meeting
September 15-18, 2010
Melbourne, Australia

Stem Cells and Regeneration
October 3-9, 2010
Woods Hole, United States

American Association of Blood Banks (AABB) Annual Meeting 2010
October 9-12, 2010
Baltimore, United States

Fraunhofer Life Science Symposium Leipzig 2010
October 29-30, 2010
Leipzig, Germany

52nd American Society of Hematology (ASH) Annual Meeting and Exposition
December 4-7, 2010
Orlando, United States

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.



JOB OPPORTUNITIES


Senior Scientist – Magnetic Cell Separation (STEMCELL Technologies)

Business Development Manager Europe – Cell Therapy Products (Pall Corporation)


Manager/Sr. Manager, Therapeutic Cell Solutions, Process Development (Lonza)” target=”_blank” href=”http://cl.exct.net/?qs=ee4a9b163e6ccad6c08f6ca4355f928a877d7c021b02577c2796a427b0802610″>Manager/Sr. Manager, Therapeutic Cell Solutions, Process Development (Lonza)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.

Visit here to post your career opportunities.



Have we missed an important article or publication in Hematopoiesis News? Click here to submit!



Learn more about Hematopoiesis News: Archives  |  Events  |  Subscribe  |  Contact Us